EcoDrugPlus

Fibroblast Growth Factor Receptor 1

Ensembl ID : ENSMPUG00000009649
Gene Symbol: FGFR1
2 Cross references
289 Possible Orthologues:

Fibroblast Growth Factor Receptor 2

Ensembl ID : ENSMPUG00000002989
Gene Symbol: FGFR2
4 Cross references
216 Possible Orthologues:

Fibroblast Growth Factor Receptor 3

Ensembl ID : ENSMPUG00000011055
Gene Symbol: FGFR3
2 Cross references
196 Possible Orthologues:

Fibroblast Growth Factor Receptor 4

Ensembl ID : ENSMPUG00000012284
Gene Symbol: FGFR4
2 Cross references
123 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 1

Ensembl ID : ENSMPUG00000004699
Gene Symbol: FLT1
2 Cross references
198 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 3

Ensembl ID : ENSMPUG00000005073
Gene Symbol: FLT3
2 Cross references
133 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 4

Ensembl ID : ENSMPUG00000000579
Gene Symbol: FLT4
4 Cross references
195 Possible Orthologues:

Folate Hydrolase 1

Ensembl ID : ENSMPUG00000010390
Gene Symbol: FOLH1
2 Cross references
210 Possible Orthologues:

Folate Receptor Alpha

Ensembl ID : ENSMPUG00000010228
Gene Symbol: FOLR1
2 Cross references
217 Possible Orthologues:

Follicle Stimulating Hormone Receptor

Ensembl ID : ENSMPUG00000010921
Gene Symbol: FSHR
2 Cross references
199 Possible Orthologues:

Fyn Related Src Family Tyrosine Kinase

Ensembl ID : ENSMPUG00000010284
Gene Symbol: FRK
2 Cross references
216 Possible Orthologues:

Galactosidase Alpha

Ensembl ID : ENSMPUG00000002155
Gene Symbol: GLA
2 Cross references
196 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).